Dupilumab (Dupixent) for severe eczema in infants
To find out safety and effectiveness of dupilumab (Dupixent) in infants with severe eczema.
To find out safety and effectiveness of dupilumab (Dupixent) in infants with severe eczema.
To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
Develop non-invasive measures to identify abnormal placental function in babies with and without congenital anomalies.
To test a new experimental drug Temisirolimus - Temsirolimus (also known as Torisel®) is approved for kidney cell cancer treatment in adults - in combination with approved chemotherapy drugs - in the hopes of finding a drug combination that may be effective against leukemia and non-hodgkin’s lymphoma that has come back after initial treatment. To find the highest dose that can be given without casing severe side effects.
To explore the safety and treatment effect of intravenous (IV) Remodulin as add on therapy in neonates with PPHN compared to placebo.
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.
The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.
This study aims to evaluate the side effects (good and bad) of giving Vincristine Suflate Liposome Infection (also known as Marqibo®) - a drug approved for leukemia treatment in adults but that is experimental in children - with other standard chemotherapy drugs and to measure how effective the combination is at treating children and young adults with leukemia that has come back after initial treatment.